5346-53-2

Basic information

• Product Name: 5-AMINO-4-CYANO-1-(2-HYDROXYETHYL)PYRAZOLE
• Synonyms: BUTTPARK 87\09-37;AKOS BBS-00005324;5-AMINO-4-CYANO-1-(2-HYDROXYETHYL)PYRAZOLE;5-AMINO-4-CYANO-1-(2-HYDROETHYL)PYRAZOLE;5-Amino-4-cyano-1-(2-hydroxyethyl)-1H-pyrazole;5-Amino-1-(2-hydroxy-ethyl)-1H-pyrazole-4-carbonitrile;4-Cyano-1-(2-hydroxyethyl)-1H-pyrazol-5-amine;1H-Pyrazole-4-carbonitrile, 5-amino-1-(2-hydroxyethyl)-
• CAS NO: 5346-53-2
• Molecular Formula: C₆H₈N₄O
• Molecular Weight: 152.15
• Mol File: 5346-53-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 158-160 °C
• Boiling Point: 424.9oC at 760 mmHg
• Flash Point: 210.8oC
• Appearance: Off-white/Crystalline Solid
• Density: 1.42g/cm3
• Vapor Pressure: 5.63E-08mmHg at 25°C
• Refractive Index: 1.657
• PKA: 14.26±0.10(Predicted)
• CAS DataBase Reference: 5-AMINO-4-CYANO-1-(2-HYDROXYETHYL)PYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-4-CYANO-1-(2-HYDROXYETHYL)PYRAZOLE(5346-53-2)
• EPA Substance Registry System: 5-AMINO-4-CYANO-1-(2-HYDROXYETHYL)PYRAZOLE(5346-53-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 5346-53-2(Hazardous Substances Data)

Usage

General Description

5-AMINO-4-CYANO-1-(2-HYDROXYETHYL)PYRAZOLE is a chemical compound with the molecular formula C7H8N4O. It is a pyrazole derivative with a cyano group and an amino group attached to the pyrazole ring, as well as a hydroxyethyl moiety. 5-AMINO-4-CYANO-1-(2-HYDROXYETHYL)PYRAZOLE is utilized in the field of pharmaceuticals, particularly in the development of new drugs and medicines. It may also be used as a building block in organic synthesis for the production of various other chemical compounds. Additionally, the presence of both an amino group and a cyano group in its structure suggests potential for biological activity and pharmacological properties, making it a target for further research in drug discovery and development.

InChI:InChI=1/C6H8N4O/c7-3-5-4-9-10(1-2-11)6(5)8/h4,11H,1-2,8H2

Upstream product

• 109-84-2 2-hydroxyethylhydrazine 
• 123-06-8 Ethoxymethylenemalononitrile 

Downstream Products

• 100524-24-1 9-(2'-hydroxyethyl)adenine 
• 58046-52-9 5-amino-1-(2-hydroxy-ethyl)-1H-pyrazole-4-carboxylic acid amide 
• 89466-60-4 1-(2-chloroethyl)-5-amino-4-cyanopyrazole 
• 6714-29-0 2,3-dihydro-1H-imidazo[1,2-b]pyrazole 
• 1362165-26-1 2-{4-amino-6-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}ethanol 
• 1361961-43-4 1-(2-chloroethyl)-6-(difluro-(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1361960-73-7 6-(difluro-(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-vinyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1361961-41-2 1-(2-chloroethyl)-6-(difluro-(4-fluorophenyl)-methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol 
• 1361960-72-6 6-(difluro-(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 174648-63-6 7-<β-(benzyloxy)ethyl>-2-(2-furyl)pyrazolo<4,3-e>-1,2,4-triazolo<1,5-c>pyrimidine 
• 174648-72-7 5-amino-1-<β-(benzyloxy)ethyl>-4-<3-(2-furyl)-1,2,4-triazol-5-yl>pyrazole 

Relevant articles and documents

TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.

Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: Potent and selective A2A adenosine antagonists

A series of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives (10a-o,q,r), bearing alkyl and aralkyl chains on positions 7 and 8, were synthesized in the attempt to obtain potent and selective antagonists for the A2A adenosine receptor subtype. The compounds were tested in binding and functional assays to evaluate their potency for the A2A compared with the A1 adenosine receptor subtype. In binding studies in rat brain membranes, most of the compounds showed affinity for A2A receptors in the low nanomolar range with a different degree of A2A versus A1 selectivity. Comparison of N7 (10a-d,h-o)- and N8 (10e-g)-substituted pyrazolo derivatives indicates that N7 substitution decreases the A1 affinity with the concomitant increase of A2A selectivity. Specifically, the introduction of a 3-phenylpropyl group at pyrazolo nitrogen in position 7 (101) increased significantly the A2A selectivity, being 210-fold, while the A2A receptor affinity remained high (Ki = 2.4 nM). With regards to the affinity for A2A receptors, also the compound 10n, bearing in the 7-position a β-morpholin-4-ylethyl group, deserves attention (K1 = 5.6 nM) even though the A2A selectivity (84-fold) was not as high as that of 101. Conversely, the compound 10m (N7-4-phenylbutyl derivative) showed a remarkable selectivity (A1/A2A ratio = 129) associated with lower A2A affinity (K1 = 21 nM). In functional studies, most of the compounds examined reversed 5′-(N-ethylcarbamoyl)adenosine-induced inhibition of rabbit platelet aggregation inhibition which is a biological response mediated by the A2A receptor subtype. The compounds are potent and selective A2A antagonists which can be useful to elucidate the pathophysiological role of this adenosine receptor subtype. These compounds deserve to be further developed to assess their potential for treatment of neurodegenerative disorders such as Parkinson's disease.

Pyrazolopyridine cycloalkanones and process for their preparation

Novel tetrahydropyrazolo-[3,4-b]quinolinones, cyclopenta[b]pyrazolo-[4,3-e]pyridinones and cyclohepta[b]-pyrazolo[4,3-e]pyridinones, useful as anxiolytics having reduced side effects, are disclosed, including methods of preparation, pharmaceutical compositions containing them and intermediates used in their preparation.